PFE News | Roxom Stocks

1 BTC

=

- USD

Loading market data...

PF

Mkt Cap

$157.65B

Volume

23.86M

Next Earnings

November 3rd

Chart Financials Earnings News About Dividends Insider Filings

Wall Street's Bull Case for Bristol Myers Squibb Is Getting LouderBristol Myers Squibb (BMY) is up 17% this year and trades at a discount to peers despite strong Q2 performance with $12.9B revenue and 153% EPS growth. The company's growth portfolio of newer drugs now accounts for nearly 60% of revenue and grew 15% year-over-year, offsetting concerns about patent expirations on legacy drugs. With a 3.95% dividend yield, $5B buyback program, and potential acquisition interest from AstraZeneca, analysts see significant upside potential as the market has underpriced the stock relative to its pipeline execution.The Motley Fool · Sep 20, 2026

3 Dividend Stocks to Buy and Hold for 10 YearsThe article recommends three healthcare dividend stocks for long-term investors: Pfizer, Abbott Laboratories, and Medtronic. Despite recent challenges, all three companies offer strong dividend programs with growth potential. Pfizer has a promising pipeline including weight loss and cancer drugs. Abbott benefits from a diversified medical device business and recent acquisitions. Medtronic is positioned for growth through its cardiac ablation solutions and robotic surgery systems.The Motley Fool · Sep 18, 2026

2 High-Yield Dividend Stocks to Buy and 1 to AvoidThe article recommends buying Energy Transfer and Verizon as high-yield dividend stocks, while advising investors to avoid Pfizer. Energy Transfer benefits from AI data center demand for natural gas with a 6.4% yield and strong growth prospects. Verizon offers a 5.8% yield with improving subscriber metrics and fiber growth opportunities. Pfizer is flagged as risky due to unsustainable dividend payouts exceeding free cash flow, high debt from the Seagen acquisition, and an upcoming patent cliff on blockbuster drugs.The Motley Fool · Sep 18, 2026

If a Recession Is Coming, History Says This 1 No-Brainer ETF Is the Smartest Buy Right NowWith bond market signals suggesting potential recession risks, the Invesco S&P 500 High Dividend Low Volatility ETF (SPHD) is positioned as a defensive investment option. The ETF gained 0.6% in 2022 when the S&P 500 fell 18.2%, offering exposure to recession-resilient sectors like consumer staples and healthcare while avoiding volatile tech stocks. Its 4.82% dividend yield and low volatility make it attractive for risk-averse investors seeking portfolio protection.The Motley Fool · Sep 18, 2026

Autoimmune Disease Therapeutics Market Set for Growth Through 2034 as Biologics, Precision Medicine and Pipeline Innovation Reshape the Competitive LandscapeThe global autoimmune disease therapeutics market is projected to grow from USD 132.75 billion in 2025 to USD 254.60 billion by 2034, at a CAGR of 7.5%. Growth is driven by rising autoimmune disease diagnoses, increased adoption of biologics and targeted oral therapies, biosimilar expansion, and emerging cell and gene therapies. Biologics dominate with 66% market share, TNF inhibitors lead drug classes at 29%, and rheumatoid arthritis accounts for 34% of revenue. North America holds 44% regional share while Asia-Pacific is expected to grow fastest.GlobeNewswire Inc. · Sep 17, 2026

Is Cancer the Turnaround Moderna Has Been Looking for Post-COVID?Moderna reported positive Phase III results for its personalized mRNA cancer therapy (intismeran autogene) developed with Merck, showing significant improvements in recurrence-free and distant metastasis-free survival in melanoma patients. The breakthrough validates Moderna's mRNA platform beyond vaccines and opens opportunities across multiple tumor types, while the company simultaneously expands its respiratory vaccine portfolio with RSV, flu, and combination vaccines to reduce COVID-19 dependence.Zacks Investment Research · Sep 15, 2026

4 Prostate Cancer Drug Stocks to Watch During Awareness MonthAs prostate cancer incidence rises with advanced-stage diagnoses increasing, four pharmaceutical companies are advancing treatments. Pfizer and Novartis, with established prostate cancer franchises, await FDA decisions on label expansions for Talzenna/Xtandi and Pluvicto respectively. Candel and Janux, earlier-stage developers, are preparing regulatory filings and advancing clinical programs in this growing market.Zacks Investment Research · Sep 15, 2026

Immunotherapy Drugs Market 2026: Precision Medicine, Next-Generation Biologics and Expanding Cancer Indications Fuel Growth OpportunitiesThe global immunotherapy drugs market is experiencing significant growth driven by advances in biotechnology, rising demand for targeted treatments, and expanding therapeutic applications across cancer, autoimmune, and inflammatory diseases. Key growth factors include increasing disease burden, robust drug pipelines, personalized medicine adoption, and combination therapy development. The Americas and Europe remain dominant markets, while Asia-Pacific is emerging as a high-growth region. Major pharmaceutical and biotech companies are increasing R&D investments and collaboration to accelerate innovation.GlobeNewswire Inc. · Sep 15, 2026

Should iShares Select Dividend ETF (DVY) Be on Your Investing Radar?The iShares Select Dividend ETF (DVY) is a large-cap value ETF with $23.60 billion in assets and a 0.38% expense ratio. It has delivered 16.75% returns year-to-date and 18.11% over the past year, with a 3.24% dividend yield. The ETF holds 106 stocks with heavy exposure to Financials (25.7%), Utilities, and Consumer Staples. While rated a 'Hold' by Zacks, investors should consider lower-cost alternatives like SCHD (0.06% expense ratio) and VTV (0.03% expense ratio).Zacks Investment Research · Sep 15, 2026

AZN's Etcamah Fails Late-Stage Study for First-line Breast CancerAstraZeneca announced that its phase III SERENA-4 study evaluating Etcamah combined with Pfizer's Ibrance failed to meet its primary endpoint of progression-free survival as first-line treatment for ER-positive, HER2-negative advanced breast cancer, though numerical improvement was observed. The failure does not affect Etcamah's recent FDA approval for a switch strategy in patients with ESR1 resistance mutations.Zacks Investment Research · Sep 14, 2026

PF

PFEPfizer Inc.

PFE

Pay with—

Available Balance0.00

Your PositionYou don't own any PFE yet.

Related Tickers

Earnings

Dividends

Last · Jul 24Quarterly

Amount$0.43

Yield6.23%

Annual$1.72